Bispecific Antibody Market Size & Share, by Drugs (Catumaxomab, Blinatumomab, Duligotumab); Indication (Autoimmune Diseases, Oncology); End-user (Homecare, Hospitals, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5042
  • Published Date: Jun 17, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Bispecific Antibody Market size is expected to cross USD 1 Billion by the end of 2035, growing at a CAGR of 7% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of bispecific antibody was around USD 500 Million. The market is primarily driven by a rise in the number of cancer-afflicted people. Simply owing to population increase and aging, the worldwide burden of cancer is anticipated to rise to 27.5 million new cases and 16.3 million cancer deaths by 2040. Bispecific antibodies are a type of immunotherapy that has shown promising results in cancer treatment. Also, it can redirect and activate immune cells to specifically target cancer cells.

Besides this, rising facilities for rare diseases can facilitate access to bispecific antibodies for treatment. On May 4, 2023, the National Organization for Rare Disorders (NORD) unveiled the opening of nine additional Rare Disease Centers of Excellence, bringing the total number of medical facilities of NORD in the United States to 40. Rare diseases are typically associated with unmet medical needs, the establishment of specific facilities will increase the need for antibodies for the treatment of rare diseases.


Bispecific Antibody Market
Get more information on this report: Request Free Sample PDF

Bispecific Antibody Market: Growth Drivers and Challenges

Growth Drivers

  • Rising Approvals for Antibodies – The approval of antibodies provides healthcare providers with an additional treatment option for various diseases. At the start of November 2021, seven antibody products that addressed the COVID-19 virus, developed as either monotherapy or in combination with anti-SARS-CoV-2 mAbs, have been approved or had obtained emergency use authorizations (EUAs).
  • Rising Benefits of Bispecific Antibody – According to the results of phase I/II clinical trial of REGN5459 reported at the AACR Annual Meeting 2023, patients with multiple myeloma that has recurred or who were treated with the two highest doses of REGN5459, a bispecific antibody addressing BCMA and CD3, saw a 90.5% overall response rate. The rising research and development have advanced the efficacy of bispecific antibodies for enhanced therapeutic compared to traditional monoclonal antibodies.
  • Rising Advancement in Protein Engineering – In January 2022, Amgen collaborated with Generate Biomedicines, for discerning protein engineering and developing bioengineered protein drug for five new clinical trials targeting different areas. Bispecific antibodies have gained significant utility in the field of protein engineering owing to their use in binding the two different proteins, enabling the modulation of protein-protein interactions. This capability opens up possibilities for therapeutic interventions and functional studies in protein engineering.

Challenges

  • The Drug Development is Expensive- The initial stage of drug development involves extensive research and discovery efforts, including target identification, compound screening, and preclinical testing. These activities require significant investment in scientific expertise, laboratory facilities, and equipment. R&D costs account for a substantial portion of the overall expenses in drug development.
  • Lack of Adequate Healthcare Infrastructure
  • Insufficient Medical Reimbursement Policies

Bispecific Antibody Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~7%

Base Year Market Size (2022)

~ USD 500 Million

Forecast Year Market Size (2035)

~ USD 1 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Bispecific Antibody Segmentation

Indication (Autoimmune Diseases, Oncology)

The oncology segment in the bispecific antibody market is poised to have the largest revenue share of about 65% till 2035. The rise in the development of therapies for cancer is expected to drive the segment’s gain. Since 2000, the number of cancer-targeting clinical studies has nearly quadrupled, rising from 421 in 2000 to 1,489 in 2021. Furthermore, the cases of cancer are predicted to rise in coming years, owing to the obese and unhealthy lifestyle of humans. Excess body weight is responsible for roughly 5% of new cancer cases in men and 10% in women each year. Bispecific antibodies can be combined with targeted agents, such as small molecule inhibitors or monoclonal antibodies, to achieve synergistic effects. By simultaneously targeting tumor cells and specific signaling pathways or growth factor receptors, bispecific antibodies in combination with targeted agents can enhance the anti-cancer activity and overcome resistance mechanisms, improving treatment outcomes.

End-Users (Homecare, Hospitals, Specialty Clinics)

The hospital segment in the bispecific antibody market will accumulate a significant portion of around 46% in the year 2035. Around 25% of patients died in a hospital in the United States, with 62% having been admitted at least once in the previous month. Furthermore, in their last and critical time of life, 29% of patients had been taken to an intensive care unit. They can target specific cancer cells while simultaneously engaging the immune system to enhance anti-tumor immune response. Bispecific antibodies can be administered as part of immunotherapy regimens, such as immune checkpoint inhibitors or CR-T cell therapies, to improve treatment outcomes and patient responses at hospitals.

Our in-depth analysis of the global bispecific antibody market includes the following segments:

     Drugs

  • Catumaxomab
  • Blinatumomab
  • Duligotumab

     Indication

  • Autoimmune Diseases
  • Oncology

     End User

  • Homecare
  • Hospitals
  • Specialty Clinics

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Bispecific Antibody Market - Regional Synopsis

North American Market Forecast

The North American region is projected to hold over 35% share of the global bispecific antibody market by the end of 2035, due to rising demand for targeted and personalized therapies. For the previous eight years, personalized medicines have been responsible for at least twenty-five percent of new drug approvals in the United States. Moreover, in 2022, twelve personalized medications have been approved, accounting for about 34 percent of all freshly approved therapeutic molecular entities. This customization enables the development of therapies that are tailored to the molecular profile of a patient’s tumor potentially increasing treatment efficacy and reducing adverse effects. Hence, it is set to drive the expansion of the bispecific antibody market in the region.

APAC Market Statistics

The Asia Pacific bispecific antibody market is estimated to be the 2nd largest, with a share of about 24% by the end of 2035. Rising government initiatives for the treatment of rare diseases. In March 2021, the government announced the National Policy for Rare Diseases (NPRD), 2021 in India, to help patients with rare diseases. The government intends to provide financial assistance of up to USD 61, 146 to individuals suffering from any category of Rare Diseases. Moreover, there is also a provision for proving the treatment in any of the Centre of Excellence falls under NPRD-2021. Such initiatives focused on improving patient access to bispecific antibody treatments for rare diseases. This may include insurance coverage and reimbursement of these therapies, ensuring that patients can afford and access these innovative treatments.

Research Nester
Bispecific Antibody Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Bispecific Antibody Market

top-features-companies
    • F. Hoffmann-La Roche Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Innovent Biologics, Ltd.
    • Affimed GmbH
    • Pieris Pharmaceuticals, Inc.
    • Mereo BioPharma Group plc
    • TG Therapeutics, Inc.
    • MacroGenics, Inc.
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • AbbVie, Inc.

In-the-news

In The News

  • GlaxoSmithKline plc in a joint venture with Vir Biotechnology, Inc. announced the collaboration with the government of the United States. With this agreement, the companies will fulfill the need for 600,000 extra doses of Sotrovimab, it is a monoclonal antibody for the early treatment of COVID-19.
  • AbbVie Inc. announced the approval of the U.S. FDA for the world’s first and only T-cell-engaging bispecific antibody, EPKINLY. It is targeted for the treatment of persistent or refractory diffuse large B-cell lymphoma (DLBCL) in adults.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5042
  • Published Date: Jun 17, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing prevalence of cancer, a higher instance of autoimmune diseases, and advancement in the bispecific antibody are the major factors driving the market growth.

The market size of bispecific antibody is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Innovent Biologics, Ltd., Affimed GmbH, Pieris Pharmaceuticals, Inc., Mereo BioPharma Group plc, TG Therapeutics, Inc., Pfizer Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., and AbbVie, Inc.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drugs, indication, end user, and by region.

The oncology segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Shortage of adequate medical supplies and the high cost of developing the drug is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Bispecific Antibody Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying